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INTRODUCTION
Neuroendocrine tumors (NET) were previously called carcinoid
tumors (1). NET can be divided into five types of tumors accord-
ing to World Health Organization (WHO) classification of tumors of
the digestive system, 2010 : NET G1, NET G2, neuroendocrine car-
cinoma (NEC) (large cell or small cell type), mixed adenoneuroen-
docrine carcinoma (MANEC), and hyperplastic and preneoplastic
lesions (2). Most cases are classified into former three groups.
NET is a rare neoplasm that includes carcinoid, neuroendocrine
carcinoma and small cell carcinoma. G stands for grading accord-
ing to mitotic count and Ki-67 index. NET G1 is usually benign,
whereas NET G2 and NEC are malignant. Tumor capacity is meas-
ured by Ki-67 staining with Ki-67 index=2% seen in G1 tumors,
3% -20% in G2 tumors, and20% tumor cell involvement in NEC
(2). NEC is a relatively rare tumor in the stomach (3, 4). It exhibits
aggressive growth which results in vascular invasion and early dis-
tant metastasis, and has a poor prognosis (5, 6).
Here we report a case of NET G2 in the stomach that showed
an intriguing endoscopic finding.
CASE REPORT
A 61-year-old Japanese male patient presented with a 1-month
history of abdominal fullness. Patient interview revealed no par-
ticular past history, family history or social history. On physical
examination, right upper quadrant or epigastric hard mass was
easily palpable. A blood laboratory test showed anemia (hemoglo-
bin 10.5 g/dl), hyperleukocytosis (10,800/mm3 with 7,660/mm3
of neutrophils), raised C-reactive protein (3.3 mg/dl) and elevated
erythrocyte sedimentation rate (64 mm/hour). Serum CEA and
CA19-9 were within normal range. Examination by esophagogas-
troduodenoscopy revealed a whitish cauliflower-shaped Borrmann
type I tumor on the lesser curvature of the gastric antrum (Fig. 1).
Histological biopsies of the lesion revealed the diagnosis of NET
G2. Computed tomography (CT) showed a gastric tumor with an-
other big mass which seems to be a lymphadenopathy around the
posterior of the hepatic left lobe and epigastric lesion (Fig. 2).
Whole body positron emission tomography (PET)/CT image dem-
onstrates an intense uptake of 18F-fluoro-2 -deoxyglucose (FDG)
in the lesser curvature of the stomach (SUVmax 10.4) and in sev-
eral perigastric lymph nodes (SUVmax 5.3), but did not detect any
distant metastasis. Endoscopic and transabdominal ultrasonogra-
phy (EUS) showed an isoechoic tumor mainly in the mucosal and
submucosal layer and the tumor developed into deeper layer (Fig.
3). He underwent a distal gastrectomy with D2 lymphadenectomy.
A Billroth type I anastomosis was done. The resected tumor showed
Borrmann type I mass 67 cm in size. Microscopically, the tumor
was composed of malignant large cells with rich cytoplasm, and
large, round, clear nuclei. The tumor cells were arranged to form
solid nests or sheet- like structures. Immunohistochemical analy-
sis revealed that the tumor cells were positive for CD56 and syn-
aptophysin, but negative for chromogranin A (Fig. 4). The tumor
had infiltrated the subserosal layer and lymph node metastasis
was found in 6 of 42 lymph nodes. The Ki-67 labeling index was
10%. These findings led to the diagnosis of NET G2 according to
the 2010 WHO criteria. His performance status (PS) has been 3
after operation. Therefore, he was not treated by adjuvant che-
motherapy. His PS improved into 1 by inpatient and outpatient
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Fig. 1 The esophagogastroduodenoscopy finding revealed a whitish cauliflower-shaped Borrmann type I tumor on the lesser curvature of the
gastric antrum.
Fig. 2 Abdominal computed tomography (CT) findings of the patient. CT revealed a mass in the lesser curvature of the gastric antrum (a) and
enlarged lymph nodes (b).
Fig. 4 Hematoxylin and eosin (H&E) staining and immunohistochemical stainings of the tumor cells. Large cells with high nuclear to cytoplasm
ratio (a). The cells were positive for CD56 (b) and synaptophysin (c). (a400, b, c200)
Fig. 3 Endoscopic (a) and transabdominal (b) ultrasonography showed an isoechoic mass located in the mucosal and submucosal layers and
invaded partially into deeper layer.
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hospital treatment, but liver and lymph node metastases were re-
vealed by follow up computed tomography 11 months later. Bi-
weekly irinotecan (CPT-11) plus cisplatin (CDDP) chemotherapy
(CPT-11 60 mg/m2 and CDDP 30 mg/m2 on day 1) was treated
since then. The patient had a partial response at first and received
them for 9 months. His anorexia and liver injury got worse into
grade 3 and the chemotherapy was impossible to be continued.
The tumor was regrown and he died of multiple hepatic metasta-
ses after 31 months from operation.
DISCUSSION
Gastric NEC is a rare tumor, which reportedly comprises 0.1-
0.6% of gastric cancers (3, 7, 8). NEC is deeply invasive and metas-
tatic. The diagnostic rate by biopsies under esophagogastroduo-
denoscopy is very low (11-27%) (9, 10), because the tumors of
most cases contain adenocarcinoma components. The biopsied
specimen of our case was immune-stained positively with synap-
tophysin and CD56. It comprises NET G2 and seems to be classi-
fied as a pure type according to the pathological examination of the
resected tumor (5). The Ki-67 labeling index of this tumor was
10% in the component and the diagnosis was NET G2 according
to the 2010 WHO classification. But the growth was very progres-
sive and invasive. The clinical course of our case seems to be de-
fined as carcinoma. Spampatti et al. (11) reported the case of gas-
tric NET G1 with 6 mm in size and a Ki-67 of less than 2% which
proceeded into 7 cm of NEC with both hepatic and massive peri-
toneal metastases (Ki-67 40%) after 8 years. Gastric NET G1 or
G2 may have a malignant potential and should be followed up care-
fully. Large cell neuroendocrine carcinoma of the stomach is rare
and also a small percentage of all gastric endocrine tumors (12). It
is significantly more aggressive than that of gastric adenocarcinoma
(12). Pathological examination of this component in our case is
large cell type. The clinical course of large cell type NET G1 or G2
may be similar with gastric NEC.
Rindi et al. (13) classified gastric NETs into three types based
on the clinical characteristics. Type 1 NETs are the most frequent
(70-80% of all cases) and associated with type-A chronic atrophic
gastritis. Type II NETs are rare and occur in association with
Zollinger-Ellison syndrome in multiple endocrine neoplasia type I
(MEN-1). Type III NETs are the second most common and occur
in a sporadic and solitary large form. Our case had Helicobacter
pylori positive gastritis, and his tumor is classified into type III
NET.
Apart from the regional lymph nodes, the liver is the most fre-
quent site of NET and liver metastases are major prognostic factor
of NET (14). Our patient with gastric NET G2 developed liver me-
tastasis 11 months after gastrectomy. Shin et al. reported that one
of eight patients who have gastric NET with liver metastases was
G2 and others were NEC (15). Another factor, like unknown pri-
mary tumor as reported (15), other than histological grade may
affect the prognosis.
61 cases of gastric endocrine carcinoma were reported with de-
scription or in the photo of the upper gastrointestinal endoscope.
13 cases (21%) were Borrmann type I, 25 cases (40%) were type
II, 15 cases (24%) were type III, 1 case was type IV, 1 case was
type V, and 5 cases were type 0 (IIa 1 case ; IIc 3 cases ; IIa+IIc 1
case). One case showed the morphology of submucosal tumor.
A rare polypoid type early NEC in the stomach was reported (16).
Endoscopic findings of the tumor also demonstrated a polypoid
lesion with a broad stalk. The surface showed a white coat, erosion
and lobulation and the macroscopic finding was unique and similar
with the one of our case. The mass of our case is whitish Borrmann
I and looks like cauliflower. The tumor infiltrated into the subse-
rosa in association with lymphangioinvasion. Gastric NEC arises
predominantly from endocrine precursor cell clones that develop
in the preceding adenocarcinoma component. These clones trans-
form into NEC and the NEC develops rapidly in the submucosal
and deeper layer (17). According to the histological examination,
a wide range of necrosis by the metastatic cancer was observed in
the lymphatic ducts of the tumor. Probably those things contribute
to the color and the shape of the tumor.
Treatment of localized gastric NETs usually involves surgical re-
section, and surgery is the only curative treatment for NETs. Che-
motherapy has recently been recommended to be administered
to NEC patients following gastrectomy. There is no standardized
chemotherapy for gastric NET. Chemotherapeutic regimens includ-
ing cisplatin, irinotecan, etoposide, doxorubicin, and vincristine are
reported. Kulke et al. (18) reported a very low response rate to
cisplatin plus irinotecan for extra-pulmonary NETs, however, Okita
et al. (10) reported the response rate to cisplatin plus irinotecan for
gastric poorly differentiated NEC was 75%. Large-scale retrospec-
tive analyses for advanced neuroendocrine carcinoma of the diges-
tive system by Japanese group demonstrate that irinotecan plus
cisplatin (IP) and etoposide plus cisplatin (EP) are the most com-
monly used regimens (19). IP was the most commonly selected
regimen, especially for the gastrointestinal tract in the Japanese
study (19), while EP was the most commonly selected regimen in
the Nordic study (20). The response rate of IP was slightly better
than that of EP for the treatment of NEC, even after adjusting pa-
tient background by multivariate analysis. The median overall sur-
vival of gastric NEC patients is 13.3 months. We chose IP che-
motherapy and the overall survival of our case was much longer,
although the tumor is classified into NET G2 and our case is hard
to compare with the cases of NEC simply. Because a part of NET
G2 actually embraces a very aggressive profile and has rather a
G3-NET-like behavior, chemotherapy might become the first op-
tion therapy (21). However, gastric NETs are not discussed in
independent, large-scaled prospective studies and tend to be ex-
cluded from clinical trials, because the cases are few (22). Sys-
tematic study of the treatment for NET G2 of digestive system
should be considered in the future.
Somatostatin analogues (SSAs) have shown to be effective in the
treatment of midgut NETs (23). Type I and II gastric NETs are
gastrin-dependent and associated with conditions inducing hyper-
gastrinemia. SSAs have been increasingly used in the treatment of
patients with type I and II gastric NETs (24), based on their capa-
bility to lower the elevated gastrin levels and suppress enterochro-
maffin like cell hyperplasia. As stated above, our case seemed to
belong to type III gastric NET and serum gastrin level in our case
was within normal range (our case 184 pg/ml ; normal values 42-
200 pg/ml) (11, 25). Management of type III gastric NET is com-
parable to that used for gastric adenocarcinomas. SSAs are consid-
ered to be a beneficial treatment in well -differentiated NET G1 and
might also be applied to control clinical symptoms in NET G2 with
higher proliferation like our case (26).
Interferon alpha along with SSAs has been used as a treatment
of midgut NETs, although often with potentially high toxicity (27).
Everolimus, an inhibitor of mammalian target of rapamycin (mTOR),
and sunitinib, an inhibitor of multi - targeted tyrosine kinase, are
reported to give a statistically significant survival benefit in entero-
pancreatic NET (28, 29).
Recently, bevacizumab, a monoclonal antibody targeting vascular
endothelial growth factor (VEGF), has shown promising results in
gastroenteropancreatic NETs, because gastroenteropancreatic
neuroendocrine tumors are known as hypervascular tumors with
increased expressions of VEGF and VEGF receptors (30, 31). Table
1 summarizes clinical trials for gastroenteropancreatic NET G1/
G2. The combination with bevacizumab, SSAs, cytotoxic chemo-
therapy or mTOR inhibitors may be a promising strategy in the
patients with gastric NET G1/G2.
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Table 1. Summary of the clinical trials for gastroenteropancreatic NET
Regimen Sites of NETs No. ofcases
Response
rate (%)
median OS
(months)
median PFS
(months) Author year Design
streptozocin+doxorubicin pancreas 38 69 26.4 18 Moertel et al. (32) 1992 Phase III
streptozocin+ fluorouracil pancreas 34 45 16.8 14 Moertel et al. (32) 1992 Phase III
chlorozotocin pancreas 33 30 18 17 Moertel et al. (32) 1992 Phase III
dacarbazine pancreas 50 34 19.3 N/R Ramanathan et al. (33) 2001 Phase II
intestine 56 16 20 N/R Bukowski et al. (34) 1994 Phase II
temozolomide+ thalidomide pancreas 11 25 Not reached Not reached Kulke et al. (35) 2006 Phase II
gastrointestine 15 7 N/R N/R Kulke et al. (35) 2006 Phase II
temozolomide pancreas, gastrointestine,bronchus, thymus 36 14 16 7 Ekeblad et al. (36) 2007
bevacizumab+ temozolomide pancreas, midgut,bronchus, unknown 34 15 33.3 11 Chan et al. (37) 2012 Phase II
temozolomide+capecitabine pancreas 30 70 Not reached 18 Strosberg et al. (38) 2011
streptozocin+doxorubicin+
fluorouracil pancreas 84 39 27 18 Kouvaraki et al. (39) 2004
streptozocin+
cyclophosphamide gastrointestine 47 26 12.5 N/R Moertel et al. (40) 1979
streptozocin+ fluorouracil 42 33 11.2 N/R
dorubicin gastrointestine 81 21 11.1 N/R Engstrom et al. (41) 1984
streptozocin+ fluorouracil 80 22 14.9 N/R
dorubicin+ fluorouracil gastrointestine 85 16 15.7 4.5 Sun et al. (42) 2005 Phase II/III
streptozocin+ fluorouracil 78 16 24.3 5.3
cisplatin+etoposide pancreas, gastrointestine(NET G1/G2, NEC) 36 55 19 N/R Fjallskog et al. (43) 2001
cisplatin+ irinotecan pancreas, gastrointestine(NET G1/G2, NEC) 15 7 11.4 N/R Kulke et al. (44) 2006 Phase II
sunitinib pancreas 86 9.3 Not reached 11.4 Raymond et al. (29) 2011 Phase III
everolimus pancreas 207 5 Not reached 11 Yao et al. (28) 2011 Phase III
everolimus+octretide LAR
(RADIANT-2) pancreas, gastrointestine 173 N/R N/R 14.3
Pavel et al. (45),
Anthony et al. (46) 2011, 2015 Phase III
everolimus+octretide LAR
(ITMO group study)
pancreas, gastrointestine,
lung 50 18 Not reached Not reached Bajetta et al. (47) 2014 Phase II
temsirolimus+bevacizumab pancreas 56 41 34 13.2 Hobday et al. (48) 2014 Phase II
bevacizumab+depot
octreotide+PEG-IFN alpha -2b pancreas 44 18 N/R 16.5 Yao et al. (49) 2008 Phase II
bevacizumab+capecitabine
(BETTER trial) gastrointestine 49 18 Not reached 23.4 Mitry et al. (50) 2014 Phase II
bevacizumab+5-FU/
streptozocin (BETTER trial) pancreas 34 44 Not reached 23.7 Ducreux et al. (51) 2014 Phase II
bevacizumab+everolimus pancreas, gastrointestine 39 26 N/R 14.6 Yao et al. (52) 2015 Phase II
bevacizumab+octreotide+
metronomic capecitabine pancreas, gastrointestine 45 17.8 N/R 14.9 Berruti et al. (53) 2014 Phase II
Methoxyestradiol+
bevacizumab pancreas, gastrointestine 31 0 N/R 11.3 Kulke et al. (54) 2011 Phase II
sorafenib+bevacizumab pancreas, gastrointestine 44 9.4 Not reached 12.4 Castellano et al. (55) 2013 Phase II
bevacizumab+pertuzumab+
sandostatin pancreas, gastrointestine 43 16 Not reached 8.2 Firdaus et al. (56) 2012 Phase II
bevacizumab+octreotide+
metronomic temozolomide pancreas, gastrointestine G2 15 64 N/R 9 Koumarianou et al. (57) 2012 Phase II
octretide LAR (PROMID trial) small intestine (midgut) 42 2.3 N/R 14.3 Rinke et al. (23) 2009 Phase III
5 - fluorouracil+octretide LAR pancreas, colon, smallintestine, unknown 29 24 Not reached 22.6 Brizzi et al. (58) 2009 Phase II
pazopanib pancreas, gastrointestine 37 18.9 Not reached 9.1 Ahn et al. (59) 2013 Phase II
thalidomide pancreas, gastrointestine 18 0 N/R N/R Varker et al. (60) 2008 Phase II
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